阿帕他胺治疗转移性前列腺癌的临床效果分析  

Clinical effect analysis of apalutamide in the treatment of metastatic prostate cancer

作　　者：赵晶 张军宏 Zhao Jing;Zhang Junhong(Dingxi People’s Hospital,Dingxi,Gansu 743000,China)

机构地区：[1]甘肃省定西市人民医院,甘肃定西743000

出　　处：《首都食品与医药》2024年第14期79-80,共2页Capital Food Medicine

基　　金：定西市科技局重点技术攻关专项(DX2023BZ19)。

摘　　要：目的探讨比卡鲁胺和阿帕他胺对转移性前列腺癌临床效果。方法选取2021年5月-2023年8月定西市人民医院泌尿外科收治且符合纳入和排除标准的100例转移性前列腺癌患者为研究对象,对照组患者50例采用口服比卡鲁胺治疗,实验组50例采用口服阿帕他胺治疗,两组患者均随访观察。统计分析两组治疗前和治疗后3个月血清前列腺特异性抗原(tPSA)水平、疼痛缓解率,比较两组治疗效果。结果①治疗前两组患者的tPSA水平无显著性差异(P>0.05),实验组患者在治疗后3个月血清tPSA水平显著低于对照组(P<0.05),两组治疗后3个月和治疗前相比,均有显著性差异(P<0.05);②实验组疼痛缓解病例、疼痛缓解率显著高于对照组(P<0.05)。结论转移性前列腺癌患者使用阿帕他胺可明显降低患者血清前列腺特异性抗原,缓解疼痛,提高患者生存质量和临床效果,值得临床推广。Objective To explore the clinical effects of bicalutamide and apalutamide in metastatic prostate cancer.Methods A total of 100 patients with metastatic prostate cancer who were admitted to the Department of Urology of Dingxi People’s Hospital from May 2021 to August 2023 and met the inclusion and exclusion criteria were selected as the study subjects,50 patients in the control group were treated with oral bicalutamide,and 50 patients in the experimental group were treated with oral apalutamide,and both groups were followed up for observation.Serum prostate-specific antigen(tPSA)levels and pain relief rates before and 3 months after treatment were statistically analyzed between the two groups,and the treatment effects of the two groups were compared.Results①There was no significant difference in tPSA levels between the two groups before treatment(P>0.05),and the serum tPSA levels in the experimental group were significantly lower than those in the control group at 3 months after treatment(P<0.05),and there were significant differences between the patients at 3 months after treatment and before treatment(P<0.05).②The pain relief cases and pain relief rate in the experimental group were significantly higher than those in the control group(P<0.05).Conclusion The use of apalutamide in patients with metastatic prostate cancer can significantly reduce the serum prostate-specific antigen in patients,relieve pain,and improve the quality of life and clinical effect of patients,which is worthy of clinical promotion.

关 键 词：比卡鲁胺 阿帕他胺 转移性前列腺癌 血清前列腺特异性抗原 

分 类 号：R737.25[医药卫生—肿瘤]